Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients
NCT05046665
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
11
Enrollment
OTHER_GOV
Sponsor class
Conditions
Urothelial Carcinoma
Interventions
DRUG:
89Zr-Girentuximab
Sponsor
South Metropolitan Health Service
Collaborators
[object Object]